European project BIP-UPy is about biomedical implants

Pelvic organ prolaps (POP) and stress urinary incontinence (SUI) are common disorders affecting millions of women worldwide.

The estimated lifetime risk of POP is 30-50% and of SUI 20–40%. The lifetime risk to undergo surgery for POP or SUI is 11%. It is most frequently seen in women who have had children and/or hysterectomies and it may be a progressive condition that worsens over time. The current used techniques have been causing high complication rates.

Intracranial aneurysms are life-threatening bulges of the brain’s blood vessels. It is estimated that between 1 and 6% of the population may present them, and the associated mortality reaches 50%”. At present, the endovascular treatment of cerebral aneurysms is mainly based on platinum coils. Coils are used to fill the aneurysm sack in a manner that it creates a solid barrier that prevents further leakage or widening of the potential rupture site. However, current treatments involve high risks for the patient and high costs for the hospital.

Biomedical implants based on polymer technologies have become an indispensable part of effective modern medicine. They represent one of the most stable markets for polymers in terms of growth. According to the consultancy firm Frost & Sullivan, the total European market for polymers in medical devices (including implants) had revenues of EUR 437 million in 2008, and this is forecasted to reach EUR 664.2 million by 2015.

Throughout 4 years BIP-UPy will address the need for new biomedical implants which could be easily fine-tuned in terms of bioactivity, biodegradability and mechanical performance depending on their final clinical application.

Bioactive BIP-UPy implants aim at improving quality of life of people suffering from intracranial aneurysms and women with pelvic organ prolapse (POP) and stress urinary incontinence (SUI). The improved functionality and optimized compatibility with the body of these new implants will lead to improved patient outcome, reducing hospitalization time and other treatment-related risks. Hence, this will ultimately result in better health and a healthcare costs reduction.

BIP-UPy opens an innovative strategy for medical implants promoting a body response towards in-situ tissue-engineering and therapy.

An effective alternative to current POP and SUI treatments based on BIP-UPy will create a less risky option for the exposed women and it will create a substantial market opportunity.

BIP-UPy endovascular treatment of cerebral aneurysms will increase patient quality of life by improving the endovascular aneurysm treatment’s effectiveness, reducing implantation and long term implant migration risks, and reducing risk of leakage and distal thrombogenicity.

The clinical specific objectives targeted with the new improved bioactive biomaterials are:

  • For surgically treated POP and SUI:
    • reduce the rate of serious complications from 10% to below 3%
  • In the treatment of intracranial aneurysms:
    • reduce patient follow-up costs follow-up costs by more than 50%
    • minimize time of exposure to radiation from 1-3 hours to 10 minutes
    • decrease aneurysm recurrence from 17-33% to below 5%

The following partners are involved in this project: FUNDACIO PRIVADA ASCAMM, EINDHOVEN UNIVERSITY OF TECHNOLOGY, LODZ UNIVERSITY OF TECHNOLOGY, SUPRAPOLIX BV, CHEMPILOTS A/S, NEOS SURGERY SL, LifeTec GROUP, COLOPLAST A/S, ANTWERP UNIVERSITY HOSPITAL, KATHOLIC UNIVERSITY OF LEUVEN

For more information go to the project site.